INVESTMENT AGREEMENT dated as of December 9, 2010 between MOLECULAR INSIGHT PHARMACEUTICALS, INC. and SAVITR CAPITAL LLCInvestment Agreement • December 14th, 2010 • Molecular Insight Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS INVESTMENT AGREEMENT (together with all exhibits and schedules hereto and as the same may be amended, supplemented or otherwise modified from time to time in accordance with the terms hereof, the “Agreement”), dated as of December 9, 2010, by and among Savitr Capital LLC, a Delaware limited liability company (the “Investor”) and Molecular Insight Pharmaceuticals, a Massachusetts corporation (the “Company”) and its successors, including, as the context may require, on or after the Effective Date, as reorganized pursuant to the Bankruptcy Code.
Interim Services AgreementInterim Services Agreement • December 14th, 2010 • Molecular Insight Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Tatum, a division of SFN Professional Services LLC (“Tatum,” “we,” “us” or “our”) is pleased that Molecular Insight Pharmaceuticals, Inc. (“Company,” “you” or “your”) has selected us to provide you with outsourced interim services. The services (the “Services”) and fees will be more particularly described on the Schedule attached hereto and will be provided by the individual resource (the “Tatum Resource”) identified on such Schedule. Schedules for any additional Tatum services or personnel may be added from time to time upon the mutual written agreement of the parties. In addition, upon the request of the Company and the execution of an additional Schedule to this agreement (the “Agreement”), Tatum will provide search services to the Company, all as more particularly described on such Schedule.
SEVERANCE AGREEMENTSeverance Agreement • December 14th, 2010 • Molecular Insight Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement is entered into by and between Charles Abdalian (“Abdalian”) on the one hand, and Molecular Insight Pharmaceuticals, Inc. (the “Company”) on the other hand, as of this 22nd day of November, 2010, as a compromise and settlement of claims by Abdalian, including for payments and other consideration provided for in his existing employment agreement and change in control agreement. In consideration of the promises set forth herein, as well as the Release of Claims executed by Abdalian and the Company simultaneously herewith, the terms of which are incorporated by reference and attached hereto as Exhibit A (the “Release”), the parties agree as follows:
SEVERANCE AGREEMENTSeverance Agreement • December 14th, 2010 • Molecular Insight Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement is entered into by and between Daniel L. Peters (“Peters”) on the one hand, and Molecular Insight Pharmaceuticals, Inc. (the “Company”) on the other hand, as of this 22nd day of November, 2010, as a compromise and settlement of claims by Peters, including for payments and other consideration provided for in his existing employment agreement and change of control agreement. In consideration of the promises set forth herein, as well as the Release of Claims executed by Peters and the Company simultaneously herewith, the terms of which are incorporated by reference and attached hereto as Exhibit A (the “Release”), the parties agree as follows:
CONSULTING AGREEMENTConsulting Agreement • December 14th, 2010 • Molecular Insight Pharmaceuticals, Inc. • Pharmaceutical preparations
This Consulting Agreement (the “Agreement”) is entered into by and between Harry Stylli (“Stylli”) and Molecular Insight Pharmaceuticals, Inc. (the “Company”).
